Literature DB >> 19210519

Implications for a role of interleukin-23 in the pathogenesis of chronic gastritis and of peptic ulcer disease.

V Koussoulas1, S Vassiliou, E J Giamarellos-Bourboulis, G Tassias, A Kotsaki, C Barbatzas, M Tzivras.   

Abstract

The present study aimed to investigate the role of gastric mucosa for the secretion of interleukin (IL)-23 in chronic gastritis. One hundred and one patients were enrolled; 47 with duodenal ulcer, 33 with gastric ulcer and 31 with chronic gastritis. Biopsies were incubated in the absence/presence of endotoxins. Supernatants were collected and IL-23 and IL-1beta were measured by enzyme-linked immunosorbent assay. Scoring of gastritis was performed according to the updated Sydney score. Patients with duodenal and gastric ulcer and those with chronic gastritis had similar scores of gastritis. IL-23 was higher in supernatants of tissue samples of Helicobacter pylori-positive than of H. pylori-negative patients. No differences were recorded in concentrations of IL-23 and IL-1beta between patients with duodenal ulcer, gastric ulcer and chronic gastritis. Positive correlations were found between IL-23 of patients with both duodenal and gastric ulcer and chronic gastritis and the degree of infiltration of neutrophils and monocytes. Similar correlations were observed between IL-23 and IL-1beta. IL-23 secreted by the gastric mucosa could be implicated in the pathogenesis of chronic gastritis. IL-23 was released in the presence of H. pylori from the inflamed gastric mucosa and followed the kinetics of IL-1beta.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19210519      PMCID: PMC2673746          DOI: 10.1111/j.1365-2249.2008.03859.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Helicobacter pylori-related disease: guidelines for testing and treatment.

Authors:  W L Peterson; A M Fendrick; D R Cave; D A Peura; S M Garabedian-Ruffalo; L Laine
Journal:  Arch Intern Med       Date:  2000-05-08

2.  Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4.

Authors:  Philipp M Lepper; Martha Triantafilou; Christian Schumann; E Marion Schneider; Kathy Triantafilou
Journal:  Cell Microbiol       Date:  2005-04       Impact factor: 3.715

3.  Apoptosis induction in gastric mucous cells in vitro: lesser potency of Helicobacter pylori than Escherichia coli lipopolysaccharide, but positive interaction with ibuprofen.

Authors:  Emma Durkin; Anthony P Moran; Peter J Hanson
Journal:  J Endotoxin Res       Date:  2006

4.  Acute ulcer bleeding. A prospective randomized trial to compare Doppler and Forrest classifications in endoscopic diagnosis and therapy.

Authors:  B Kohler; M Maier; C Benz; J F Riemann
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients.

Authors:  Chuan Zhang; Nobutaka Yamada; Yun-Lin Wu; Min Wen; Takeshi Matsuhisa; Norio Matsukura
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

6.  Local cytokine response in Helicobacter pylori-infected subjects.

Authors:  C Lindholm; M Quiding-Järbrink; H Lönroth; A Hamlet; A M Svennerholm
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

Review 7.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

8.  Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent.

Authors:  K Kusugami; A Fukatsu; M Tanimoto; M Shinoda; J Haruta; A Kuroiwa; K Ina; K Kanayama; T Ando; T Matsuura
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

9.  Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.

Authors:  R M Peek; G G Miller; K T Tham; G I Perez-Perez; X Zhao; J C Atherton; M J Blaser
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

10.  Interferon gamma-signature transcript profiling and IL-23 upregulation in response to Helicobacter pylori infection.

Authors:  J R Vivas; B Regnault; V Michel; F I Bussière; P Avé; M Huerre; A Labigne; M M D' Elios; E Touati
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Jul-Sep       Impact factor: 3.219

View more
  4 in total

Review 1.  The Roles of IL-17, IL-21, and IL-23 in the Helicobacter pylori Infection and Gastrointestinal Inflammation: A Review.

Authors:  Astri Dewayani; Kartika Afrida Fauzia; Ricky Indra Alfaray; Langgeng Agung Waskito; Dalla Doohan; Yudith Annisa Ayu Rezkitha; Abdurachman Abdurachman; Takashi Kobayashi; Reny I'tishom; Yoshio Yamaoka; Muhammad Miftahussurur
Journal:  Toxins (Basel)       Date:  2021-04-28       Impact factor: 4.546

2.  Relationship between active Helicobacter pylori infection and risk factors of cardiovascular diseases, a cross-sectional hospital-based study in a Sub-Saharan setting.

Authors:  Lionel Danny Nguefak Tali; Ghislaine Florice Nintewoue Faujo; Justine Laure Nguieguia Konang; Jean Paul Dzoyem; Laure Brigitte Mabeku Kouitcheu
Journal:  BMC Infect Dis       Date:  2022-09-12       Impact factor: 3.667

3.  IL-23 Contributes to Control of Chronic Helicobacter Pylori Infection and the Development of T Helper Responses in a Mouse Model.

Authors:  Dennis J Horvath; M Kay Washington; Vicki A Cope; Holly M Scott Algood
Journal:  Front Immunol       Date:  2012-03-26       Impact factor: 7.561

4.  Proinflammatory Cytokine IL-17 Shows a Significant Association with Helicobacter pylori Infection and Disease Severity.

Authors:  Piyumali Sandareka Arachchi; Neluka Fernando; Manjula Manoji Weerasekera; Bimalka Senevirathna; Deepaka D Weerasekera; Chinthika Prabhashinie Gunasekara
Journal:  Gastroenterol Res Pract       Date:  2017-12-17       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.